Exelixis | EXEL - Ebitda





Ebitda Cambiamento Data
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
Akebia Therapeutics USD 14.03M 17.19M 2025-03
Amgen USD 5.14B 775M 2025-12
AstraZeneca USD 5.67B 1.29B 2026-03
Bayer EUR 1.97B 457M 2025-12
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Cytokinetics USD -149.83M 127.34M 2025-12
Eisai JPY 30.1B 6.62B 2025-12
Eli Lilly USD 12.14B 4.26B 2025-12
Esperion Therapeutics USD -9.93M 24.99M 2025-09
Exelixis USD 242.86M 6.08M 2025-12
Genmab DKK 186M 291M 2025-12
Glaxosmithkline GBP 4.75B 1.52B 2025-09
Incyte USD 367.97M 46.53M 2026-03
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
MacroGenics USD 21.95M 55.39M 2025-09
Merck USD 6.3B 2.09B 2025-12
Moderna USD -790M 582M 2025-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Novartis USD 5.3B 530M 2026-03
Pfizer USD 5.99B 5.23B 2026-03
Puma Biotechnology USD 729K 11.36M 2024-06
Sanofi EUR 5.66B 3.77B 2025-09
Takeda JPY 448.13B 173.98B 2025-12
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
Xencor USD -51.05M 55.28M 2025-12